DelveInsight’s ‘Hidradenitis Suppurativa (HS) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hidradenitis Suppurativa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight’s ‘Hidradenitis Suppurativa (HS) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hidradenitis Suppurativa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
“The total prevalent population of HidradenitisSuppurativain 7MM was found to be 6,851,308 in 2017.”
Scope of the report: 1. The HS report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns 2. The HS Report and Model provide an overview of the risk factors and global trends of HS in the seven major markets (7MM: US, Germany, France, Italy, Spain, and the United Kingdom, and Japan) 3. The report provides insight into the historical and forecasted patient pool of HS in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan 4. The report helps to recognize the growth opportunities in the 7MM with respect to the patient population 5. The report assesses the disease risk and burden and highlights the unmet needs of HS 6. The report provides the segmentation of the HS epidemiology by Age-specific diagnosed prevalent Cases of HS in 7MM 7. The report provides the segmentation of the HS epidemiology by Gender-specific diagnosed prevalent Cases of HS in 7MM 8. The report provides the segmentation of the HS epidemiology by Stage-Specific diagnosed prevalent Cases of HS in 7MM
Reports highlights: 1. 11-Year Forecast of Hidradenitis Suppurativa epidemiology 2. 7MM Coverage 3. Total Diagnosed prevalent Cases of Hidradenitis Suppurativa 4. Diagnosed Prevalent Cases according to segmentation: Gender-specific, Age-specific, Stage-specific Incidence 5. Treated cases of Hidradenitis Suppurativa
Table of contents: 1. Key Insights 2. Executive Summary: Hidradenitis Suppurativa (HS) 3. SWOT Analysis: Hidradenitis Suppurativa (HS) 4. Hidradenitis Suppurativa (HS) Patient Share (%) Overview at a Glance 5. Hidradenitis Suppurativa Market Overview at a Glance 6. Disease Overview: Hidradenitis Suppurativa (HS) 7. Epidemiology and Patient Population 8. Country-wise Epidemiology of HS in the 7MM 9. Appendix 10. Disclaimer 11. DelveInsight Capabilities 12. About DelveInsight
Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Kritika Rehani Email:Send Email Phone: 9193216187 Address:304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:https://www.delveinsight.com/
Maladie De Verneuil Photo – Verneuil’s disease causes skin aggravation, for the most part in areas with skin folds (armpits, crotch, rear end, under the bosoms or within the thigh). Verneuil’s disease also called as (Hidradenitis Suppurativa), is a chronic skin illness.
It begins with the development of agonizing knobs and skin abscesses. Maladie De Verneuil Photo the problem can be seen after adolescence and most normally in the second or third decade of life. This needs to prompt the theory that hormones assume a job in the pathogenesis of the infection
Verneuil’s disease influences around 1% of the populace and most usually happen after adolescence. The provocative sores that are caused, keep going for quite a long time and can deteriorate with time.
What Are The Symptoms Of Verneuil’s Disease?
swollen, excruciating knobs (little balls underneath the skin) and abscesses (knobs loaded with discharge) in spots of the body with the most perspiration organs, for example, the armpits, the crotch, and the butt-centric area.
even though the age at the beginning may differ, manifestations regularly become evident during adolescence or early adulthood,
“body wrinkles”, where there is overwhelming perspiring, for example, within the thighs, groin or the bosoms can likewise be influenced. Numerous zones can be influenced simultaneously. Sometimes, early side effects, for example, tingling or uneasiness, may go before the condition’s trademark signs.
Causes
Although the exact causes are not known, it can take the form of environmental and genetic factors.
Verneuil’s disease is still seriously under-analyzed, as per AbbVie, which is behind the crusade. A determination takes seven years by and large. A sufferer, as a rule, counsels a GP, crisis specialist or gynecologist first.
“In any case, these specialists don’t perceive the indications as HS and tell the patient they have contamination when they really have an incendiary illness.
Developmental Stages
Stage1 the presence of knobs and skin abscesses without subcutaneous expansion
Stage 2 determined abscesses and development of fistula and hypertrophic scarring
Stage 3 harm flowing with the interconnection of abscesses and fistula follows.
What Treatment Can Be Done?
Initially, the treatment does not have much impact on Verneuil’s but can help in managing the symptoms and further cure the infection to spread in other regions or parts of the body.
Doctors can provide some oral pills that can help to cure disease and fight against bacterial infections.
Besides this surgical option can be taken.
Sandra Williams
Sandra is a science enthusiast and a researcher by nature. Her articles are informative and eloquent in equal measures, and always include knowledge that is verified by authentic sources. She is a maven at health related sciences and takes an interest in new scientific findings from all facets of the subject. Her column is a ready reckoner on all that is going on in the world of scientific study, and health sciences, including disease outbreaks, their causes, and prevention measures being taken.
The global Hidradenitis Suppurativa Treatment market is estimated to be valued at XX Million US$ in 2019 and is projected to reach XX Million US$ by 2026, expanding at a CAGR of XX% during the forecast period. The report on Hidradenitis Suppurativa Treatment market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, etc. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Hidradenitis Suppurativa Treatment.
Final Report will add the analysis of the impact of COVID-19 on this industry.
Key players in global Hidradenitis Suppurativa Treatment market include:
GlaxoSmithKline
Johnson & Johnson
Merck
Pfizer
AbbVie
Allergan
AstraZeneca
Reasons to get this report:
In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Hidradenitis Suppurativa Treatment market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape, emerging and high-growth sections of Hidradenitis Suppurativa Treatment market, high-growth regions, and market drivers, restraints, and also market chances.
The analysis covers Hidradenitis Suppurativa Treatment market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Hidradenitis Suppurativa Treatment Market across sections such as also application and representatives.
Additionally, the analysis also has a comprehensive review of the crucial players on the Hidradenitis Suppurativa Treatment market together side their company profiles, SWOT analysis, latest advancements, and business plans.
The report provides insights on the following pointers:
North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Hidradenitis Suppurativa Treatment industry.
Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Hidradenitis Suppurativa Treatment industry.
Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, Netherlands, Switzerland, Belgium, China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Vietnam, Turkey, Saudi Arabia, United Arab Emirates, South Africa, Israel, Egypt, Nigeria, Brazil, Mexico, Argentina, Colombia, Chile, Peru) market size (sales, revenue and growth rate) of Hidradenitis Suppurativa Treatment industry.
Different types and applications of Hidradenitis Suppurativa Treatment industry, market share of each type and application by revenue.
Global market size (sales, revenue) forecast by regions and countries from 2020 to 2026 of Hidradenitis Suppurativa Treatment industry.
Upstream raw materials and manufacturing equipment, downstream major consumers, industry chain analysis of Hidradenitis Suppurativa Treatment industry.
Key drivers influencing market growth, opportunities, the challenges and the risks analysis of Hidradenitis Suppurativa Treatment industry.
New Project Investment Feasibility Analysis of Hidradenitis Suppurativa Treatment industry.
With tables and figures helping analyse worldwide Global Hidradenitis Suppurativa Treatment market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Some Points from TOC:
1 Industry Overview of Hidradenitis Suppurativa Treatment 2 Major Manufacturers Analysis of Hidradenitis Suppurativa Treatment 3 Global Price, Sales and Revenue Analysis of Hidradenitis Suppurativa Treatment by Regions 5 Europe Sales and Revenue Analysis of Hidradenitis Suppurativa Treatment by Countries 6 Asia Pacific Sales and Revenue Analysis of Hidradenitis Suppurativa Treatment by Countries 7 Latin America Sales and Revenue Analysis of Hidradenitis Suppurativa Treatment by Countries 8 Middle East & Africa Sales and Revenue Analysis of Hidradenitis Suppurativa Treatment by Countries 9 Global Market Forecast of Hidradenitis Suppurativa Treatment by Regions, Countries, Manufacturers, Types and Applications 10 Industry Chain Analysis of Hidradenitis Suppurativa Treatment 11 New Project Investment Feasibility Analysis of Hidradenitis Suppurativa Treatment 12 Conclusion of the Global Hidradenitis Suppurativa Treatment Industry Market Professional Survey 2020
Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided today’s businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors. Industry Research is the credible source for gaining the market reports that will provide you with the lead your business needs.
https://i2.wp.com/higenix.com/wp-content/uploads/2020/03/IRB10.png?fit=270%2C180&ssl=1180270Stevehttps://higenix.com/wp-content/uploads/2018/09/higenix-hs-treatment.pngSteve2020-03-28 14:35:212020-03-28 14:35:21Global Hidradenitis Suppurativa Treatment Market Outlook to 2026 | Research Study By Applications, Market Drivers, Growth Demand, Industry Scope and Business Opportunities
Research and Markets Logo More The report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States , EU5 ( Germany , France , Italy , Spain , and United Kingdom ) and Japan . The Hidradenitis Suppurativa market report provides current treatment practices, emerging drugs, Hidradenitis Suppurativa market share of the individual therapies, current and forecasted Hidradenitis Suppurativa market size from 2017 to 2030 segmented by seven major markets. […] The therapeutic market of Hidradenitis Suppurativa in seven major markets is expected to generate USD 798 million in 2017 and will increase in the study period 2017-2030. The Hidradenitis Suppurativa market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Hidradenitis Suppurativa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.This segment gives a through detail of Hidradenitis Suppurativa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. […] Report Highlights In the coming years, Hidradenitis Suppurativa market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Size of the market to enable the drug manufacturers to penetrate more into the market The companies and academics are working to assess challenges and seek opportunities that could influence Hidradenitis Suppurativa R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition Major players are involved in developing therapies for Hidradenitis Suppurativa.
The report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.
The Hidradenitis Suppurativa market report provides current treatment practices, emerging drugs, Hidradenitis Suppurativa market share of the individual therapies, current and forecasted Hidradenitis Suppurativa market size from 2017 to 2030 segmented by seven major markets. The report also covers current Hidradenitis Suppurativa treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Study Period: 2017-2030
Epidemiology
The Hidradenitis Suppurativa epidemiology division provide the insights about historical and current Hidradenitis Suppurativa patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Hidradenitis Suppurativa epidemiology [segmented as Total Prevalent Patient Population, Diagnosed Prevalent Patient Population, Age-specific Diagnosed Prevalent Patient Population, Gender-specific Diagnosed Prevalent Patient Population, Stage-Specific (Severity-specific) Prevalent Population, and Treated Prevalent Cases of HS] scenario of Hidradenitis Suppurativa in 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017 to 2030.
The total diagnosed incident cases of Hidradenitis Suppurativa (HS) patients were found to be more in females than in males in 7MM during the study period i.e. 2017-2030.
Drug Chapters
Drug chapter segment of the Hidradenitis Suppurativa report encloses the detailed analysis of Hidradenitis Suppurativa marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hidradenitis Suppurativa clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
Humira: AbbVie
Humira (Adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). This drug was created using phage display technology resulting in an antibody with human-derived heavy and light chain variable regions and human IgG1:k constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps.
Emerging Drugs
IFX-1: InflaRx
IFX-1 is a first-in-class monoclonal anti-complement factor C5a antibody, being developed by InflaRx for the treatment of patients with HS. It completely blocks biological activity and demonstrates high selectivity towards its target, C5a, in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5.
Cosentyx (Secukinumab): Novartis Pharmaceuticals
Cosentyx (Secukinumab) is an IL-17A monoclonal antibody that selectively binds to IL-17A and inhibits Interleukin-17A, and IL-17 promotes neutrophil activities and is marketed by Novartis. These cytokines act on many different cell types and provide defense against different extracellular pathogens causing fungal or bacterial infections.
INCB054707: Incyte Corporation
INCB054707 is a selective JAK1 inhibitor, being developed by Incyte Corporation for the treatment of patients with Moderate-to-severe HS. This therapeutic molecule is administered by an oral route of administration. Currently, the company is investigating this molecule in the Phase II stage of development for HS.
Bimekizumab: UCB Biopharma S.P.R.L
Bimekizumab is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17A and IL-17F are the most closely related members of the IL-17 family of cytokines.
Bermekimab (MABp1): Janssen Pharmaceutical
MABp1 is a recombinant human IgG1 monoclonal antibody specific for human interleukin-1, initially being developed by XBiotech for the treatment of patients with HS. Last year Jannsen pharmaceutical acquired rights for this product. It is the only antibody targeting IL-1a currently in clinical development and has the potential for superior efficacy and safety compared to the current standard of care.
Market Outlook
The Hidradenitis Suppurativa market in the 7MM is expected to change in the study period 2017-2030. The therapeutic market of Hidradenitis Suppurativa in seven major markets is expected to generate USD 798 million in 2017 and will increase in the study period 2017-2030.
The Hidradenitis Suppurativa market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Hidradenitis Suppurativa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of Hidradenitis Suppurativa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Hidradenitis Suppurativa market or expected to get launched in the market during the study period 2017-2030. The analysis covers Hidradenitis Suppurativa market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and Size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hidradenitis Suppurativa key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Hidradenitis Suppurativa emerging therapies.
Reimbursement Scenario
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In report the publisher takes reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Report Highlights
In the coming years, Hidradenitis Suppurativa market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Hidradenitis Suppurativa R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Hidradenitis Suppurativa. Launch of emerging therapies, will significantly impact the Hidradenitis Suppurativa market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hidradenitis Suppurativa
Human and murine skin wounding commonly results in fibrotic scarring, but the murine wounding model wound-induced hair neogenesis (WIHN) can frequently result in a regenerative repair response. Here, we show in single-cell RNA sequencing comparisons of semi-regenerative and fibrotic WIHN wounds, increased expression of phagocytic/lysosomal genes in macrophages associated with predominance of fibrotic myofibroblasts in fibrotic wounds. Investigation revealed that macrophages in the late wound drive fibrosis by phagocytizing dermal Wnt inhibitor SFRP4 to establish persistent Wnt activity. In accordance, phagocytosis abrogation resulted in transient Wnt activity and a more regenerative healing. Phagocytosis of SFRP4 was integrin-mediated and dependent on the interaction of SFRP4 with the EDA splice variant of fibronectin. In the human skin condition hidradenitis suppurativa, phagocytosis of SFRP4 by macrophages correlated with fibrotic wound repair. These results reveal that macrophages can modulate a key signaling pathway via phagocytosis to alter the skin wound healing fate.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
https://i2.wp.com/higenix.com/wp-content/uploads/2020/03/F1.large.jpg?fit=1050%2C1927&ssl=119271050Stevehttps://higenix.com/wp-content/uploads/2018/09/higenix-hs-treatment.pngSteve2020-03-20 23:37:012020-03-20 23:37:01Phagocytosis of Wnt inhibitor SFRP4 by late wound macrophages drives chronic Wnt activity for fibrotic skin healing
Hidradenitis suppurativa treatment also called as acne inversa, is a long term dermatological disease which occur due to swollen lumps. They are painful and break open, and release fluid or pus. The most affected areas of the body are underarms, under the breasts, and groin. Additionally, disease generally occurs due to secondary infection, obstruction of hair follicles, and inflammation of certain sweat glands which are boosting the market growth of Hidradenitis suppurativa treatment.
Furthermore, this can also cause cellulitis which is a dermatological infection that can spread in bloodstream leading occurrence sepsis that is influencing the growth of hidradenitis suppurativa treatment market. This medical condition is most common absorbed between 20-40 years of age. Prevalence of hidradenitis suppurative is seen three times more in females than in males.
Moreover, rise in population and the changes in lifestyle of individual towards smoking and obesity causing rise of dermatological diseases are some of the factors that are positively influencing the Hidradenitis suppurativa treatment market growth during the forecast period.
Major factors driving the Hidradenitis suppurativa treatment market growth are rise in clinical trials coupled with evolving treatment options, rise prevailing cases of various dermatological affected disorders, and rise investment in research and development activities. Additionally, technological advanced treatments such as laser surgeries are boosting the Hidradenitis suppurativa treatment market growth in near future.
Furthermore, FDA approvals for drug delivery and clinical trials are propelling the Hidradenitis suppurativa treatment market growth. Moreover, rise in association of Hidradenitis suppurativa with inflammatory bowel disease, cardiovascular risk factors, and metabolic syndrome are also some of the factors that are influencing the Hidradenitis suppurativa treatment market growth.
However, due to low approval chances of phase II drugs, high cost of therapy, chance of side effects, development of drug reagents to many agents used in treatment, delay in process of treatment completion which might be due to unawareness of disease to physicians are the factors hampering the Hidradenitis suppurativa treatment market growth in near future.
The global Hidradenitis suppurativa treatment market is classified on the basis of clinical stages, medications, Route of administration, end users, distribution channel and region.
Based on clinical stage, Hidradenitis suppurativa treatment market is segmented as:
Hurley Stage 1- low,
Hurley Stage 2-moderate
Hurley Stage 3-high
Based on treatment, Hidradenitis suppurativa treatment market is segmented as:
Medication
Biologics
Antibiotics
Hormonal therapy
Immune suppurativa drugs
Zinc supplements
Pain medications
Surgery
Others
Based on Route of administration, Hidradenitis suppurativa treatment market is segmented as:
Based on end users, Hidradenitis suppurativa treatment market is segmented as:
hospitals
home centers
others
Based on distribution channels, Hidradenitis suppurativa treatment market is segmented as:
hospital pharmacy
online pharmacy
retail pharmacy
others
The global market for Hidradenitis suppurativa treatment is anticipated to experience a steady growth during the forecast period. Owing to the increase in prevalence of dermatological diseases associated with various other chronic diseases creates a more lucrative opportunity for manufactures present in the Hidradenitis suppurativa treatment market.
Furthermore, increase in new product launches, technological advancement in treatment, clinical trials and others are propelling the market Hidradenitis suppurativa treatment growth over the years.
Hidradenitis suppurativa treatment Market: Regional Wise Outlook
Geographically, the hidradenitis suppurativa treatment market is segmented into North America, Europe, Latin America, South Asia, East Asia, Oceania, Middle East and Africa.
North America is dominating the Hidradenitis suppurativa treatment market owing to rise in rise in dermatological infections, increase in clinical practices, clinically trained professionals. Asia Pacific is second largest contributor in the Hidradenitis suppurativa treatment market due to rise in inflammatory skin disease, healthcare awareness, and government support.
However, Middle East and Africa are expected to experience lucrative market growth of Hidradenitis suppurativa treatment due to lack of availability skilled professionals, lack of technological penetration of healthcare treatments and others.
Some of the key players of the hidradenitis suppurativa treatment market are: Pfizer Inc., GlaxoSmithKline plc. AstraZeneca, Johnson & Johnson, AbbVie Inc., Merck & Co., Inc., TARGET Pharma Solutions, Inc., and Novartis AG.
https://higenix.com/wp-content/uploads/2018/09/higenix-hs-treatment.png00Stevehttps://higenix.com/wp-content/uploads/2018/09/higenix-hs-treatment.pngSteve2020-03-20 18:27:302020-03-20 18:27:30Access to this page has been denied.
The report delivers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.
The Hidradenitis Suppurativa market report provides current treatment practices, emerging drugs, Hidradenitis Suppurativa market share of the individual therapies, current and forecasted Hidradenitis Suppurativa market size from 2017 to 2030 segmented by seven major markets. The report also covers current Hidradenitis Suppurativa treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Study Period: 2017-2030
Epidemiology
The Hidradenitis Suppurativa epidemiology division provide the insights about historical and current Hidradenitis Suppurativa patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Hidradenitis Suppurativa epidemiology [segmented as Total Prevalent Patient Population, Diagnosed Prevalent Patient Population, Age-specific Diagnosed Prevalent Patient Population, Gender-specific Diagnosed Prevalent Patient Population, Stage-Specific (Severity-specific) Prevalent Population, and Treated Prevalent Cases of HS] scenario of Hidradenitis Suppurativa in 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017 to 2030.
The total diagnosed incident cases of Hidradenitis Suppurativa (HS) patients were found to be more in females than in males in 7MM during the study period i.e. 2017-2030.
Drug Chapters
Drug chapter segment of the Hidradenitis Suppurativa report encloses the detailed analysis of Hidradenitis Suppurativa marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Hidradenitis Suppurativa clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
Humira: AbbVie
Humira (Adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). This drug was created using phage display technology resulting in an antibody with human-derived heavy and light chain variable regions and human IgG1:k constant regions. It is produced by recombinant DNA technology in a mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps.
Emerging Drugs
IFX-1: InflaRx
IFX-1 is a first-in-class monoclonal anti-complement factor C5a antibody, being developed by InflaRx for the treatment of patients with HS. It completely blocks biological activity and demonstrates high selectivity towards its target, C5a, in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5.
Cosentyx (Secukinumab): Novartis Pharmaceuticals
Cosentyx (Secukinumab) is an IL-17A monoclonal antibody that selectively binds to IL-17A and inhibits Interleukin-17A, and IL-17 promotes neutrophil activities and is marketed by Novartis. These cytokines act on many different cell types and provide defense against different extracellular pathogens causing fungal or bacterial infections.
INCB054707: Incyte Corporation
INCB054707 is a selective JAK1 inhibitor, being developed by Incyte Corporation for the treatment of patients with Moderate-to-severe HS. This therapeutic molecule is administered by an oral route of administration. Currently, the company is investigating this molecule in the Phase II stage of development for HS.
Bimekizumab: UCB Biopharma S.P.R.L
Bimekizumab is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17A and IL-17F are the most closely related members of the IL-17 family of cytokines.
Bermekimab (MABp1): Janssen Pharmaceutical
MABp1 is a recombinant human IgG1 monoclonal antibody specific for human interleukin-1, initially being developed by XBiotech for the treatment of patients with HS. Last year Jannsen pharmaceutical acquired rights for this product. It is the only antibody targeting IL-1a currently in clinical development and has the potential for superior efficacy and safety compared to the current standard of care.
Market Outlook
The Hidradenitis Suppurativa market in the 7MM is expected to change in the study period 2017-2030. The therapeutic market of Hidradenitis Suppurativa in seven major markets is expected to generate USD 798 million in 2017 and will increase in the study period 2017-2030.
The Hidradenitis Suppurativa market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Hidradenitis Suppurativa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of Hidradenitis Suppurativa market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Hidradenitis Suppurativa market or expected to get launched in the market during the study period 2017-2030. The analysis covers Hidradenitis Suppurativa market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and Size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Hidradenitis Suppurativa key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Hidradenitis Suppurativa emerging therapies.
Reimbursement Scenario
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In report the publisher takes reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Report Highlights
In the coming years, Hidradenitis Suppurativa market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Hidradenitis Suppurativa R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Hidradenitis Suppurativa. Launch of emerging therapies, will significantly impact the Hidradenitis Suppurativa market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hidradenitis Suppurativa
Global Hidradenitis Suppurativa Treatment Market – From PMR’s Viewpoint
Decorated with a team of 300+ analysts, PMR Insights serves each and every requirement of the clients while preparing market reports. With digital intelligence solutions, we offer actionable insights to our customers that help them in overcoming market challenges. Our dedicated team of professionals perform an extensive survey for gathering accurate information associated with the market.
PMR, in its latest business report elaborates the current situation of the global Hidradenitis Suppurativa Treatment market in terms of volume (x units), value (Mn/Bn USD), production, and consumption. The report scrutinizes the market into various segments, end uses, regions and players on the basis of demand pattern, and future prospect.
In this Hidradenitis Suppurativa Treatment market study, the following years are considered to project the market footprint:
The Hidradenitis Suppurativa Treatment market research addresses the following queries:
Why end use remains the top consumer of Hidradenitis Suppurativa Treatment in region?
Which segment does the consumers highly prefer?
How will the global Hidradenitis Suppurativa Treatment market look like by the end of the forecast period?
What innovative technologies are the Hidradenitis Suppurativa Treatment players using to get an edge over their rivals?
What are the restraints affecting the growth of the global Hidradenitis Suppurativa Treatment market?
After reading the Hidradenitis Suppurativa Treatment market report, readers can
Get hints about various agreements, product launches, acquisitions, and R&D projects of different Hidradenitis Suppurativa Treatment market players.
Outline prominent regions holding significant share in the global Hidradenitis Suppurativa Treatment market alongwith the key countries.
Investigate a comparative study between leading and emerging Hidradenitis Suppurativa Treatment market vendors.
Comprehensive evaluation on the changing pattern of consumers across various regions.
Important trends affecting the adoption pattern of Hidradenitis Suppurativa Treatment in various industries.
Hidradenitis Suppurativa Treatment market players – Player 1, Player 2, Player 3, and Player 4, among others represent the global Hidradenitis Suppurativa Treatment market. The market study depicts an extensive analysis of all the players running in the Hidradenitis Suppurativa Treatment market report based on distribution channels, local network, innovative launches, industrial penetration, production methods, and revenue generation. Further, the market strategies, and mergers & acquisitions associated with the players are enclosed in the Hidradenitis Suppurativa Treatment market report.
PMR is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
